Key result
DMP 728 significantly reduced occlusive thrombus formation compared to controls (17% at 0.1 mg/kg and 0% at 1.0 mg/kg vs 100%; p<0.05) in a canine model of arterial thrombosis.
Why the study?
Does DMP 728 prevent thrombosis and rethrombosis in a canine model of arterial thrombosis?
Population
Canine model of carotid artery thrombosis
Comparison
DMP 728 (0.1 or 1.0 mg/kg, intravenously) vs Right carotid artery or saline
Design
Preclinical
Authors
Loading...
Supports GPIIb/IIIa blockade in canine thrombosis; leaves open translation to human arterial disease.
Does DMP 728 prevent thrombosis and rethrombosis in a canine model of arterial thrombosis?
Absolute Event Rate: 17% vs 100%
p-value: p=<0.05
DMP 728, a GPIIb/IIIa receptor antagonist, effectively prevents arterial thrombosis and rethrombosis in a canine model.
Rote et al. (1994) studied Arterial thrombosis. DMP 728 vs. Control (untreated vessel or saline) was evaluated on Occlusive thrombus formation (p=<0.05). DMP 728 significantly reduced occlusive thrombus formation compared to controls (17% at 0.1 mg/kg and 0% at 1.0 mg/kg vs 100%; p<0.05) in a canine model of arterial thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: